Evidence map›Paper›PMID 36717219›Full record

ArticleGut2023

Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.

Marzia Rossi, Andrea Vecchi, Camilla Tiezzi, Valeria Barili, Paola Fisicaro, Amalia Penna, Ilaria Montali, Stephane Daffis, Simon P Fletcher, Anuj Gaggar and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. HBV-driven expansion of CXCR6Innovation (Cambridge (Mass.)) · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Targeting HBV with RNA interference: Paths to cure.Science translational medicine · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. [Therapeutic strategies, practice, and prospect of a clinical cure for chronic hepatitis B in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 7 institutions in 2 countries.

Marzia Rossi *Department of Medicine and Surgery, University of Parma, Parma, Italy.ORCID 0000-0003-4336-8502
Andrea Vecchi *Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Camilla TiezziDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Valeria BariliDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Paola FisicaroUnit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.ORCID 0000-0003-3720-9214
Amalia PennaUnit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Ilaria MontaliDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Stephane DaffisGilead Sciences Inc, Foster City, California, USA.
Simon P FletcherGilead Sciences Inc, Foster City, California, USA.
Anuj GaggarGilead Sciences Inc, Foster City, California, USA.
Jonathan MedleyGilead Sciences Inc, Foster City, California, USA.
Michael GraupeGilead Sciences Inc, Foster City, California, USA.
Latesh LadGilead Sciences Inc, Foster City, California, USA.
Alessandro LoglioDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Roberta SoffrediniDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Marta BorghiDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Teresa PollicinoDepartment of Human Pathology, University Hospital of Messina, Messina, Italy.
Cristina MusolinoDepartment of Human Pathology, University Hospital of Messina, Messina, Italy.
Arianna AlfieriUnit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Federica BrilloUnit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Diletta LaccabueDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Marco MassariUnit of Infectious Diseases, IRCCS, Reggio Emilia, Italy.
Chiara BoariniDivision of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy.
Gianluca AbbatiDivision of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy.
Giuseppe PedrazziDepartment of Neuroscience - Biophysics and Medical Physics Unit, University of Parma, Parma, Italy.
Gabriele MissaleDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Pietro LamperticoDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.ORCID 0000-0002-1026-7476
Carlo FerrariDepartment of Medicine and Surgery, University of Parma, Parma, Italy carlo.ferrari@unipr.it.
Carolina BoniUnit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.ORCID 0000-0002-7630-5180
University of Parma · ITGilead Sciences (United States) · USOspedale di Parma · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Messina · ITUniversity of Modena and Reggio Emilia · ITAzienda Sanitaria Unità Locale di Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveExhausted hepatitis B virus (HBV)-specific CD8 T cells in chronic HBV infection are broadly heterogeneous. Characterisation of their functional impairment may allow to distinguish patients with different capacity to control infection and reconstitute antiviral function.

designHBV dextramer+CD8 T cells were analysed ex vivo for coexpression of checkpoint/differentiation markers, transcription factors and cytokines in 35 patients with HLA-A2+chronic hepatitis B (CHB) and in 29 control HBsAg negative CHB patients who seroconverted after NUC treatment or spontaneously. Cytokine production was also evaluated in HBV peptide-stimulated T cell cultures, in the presence or absence of antioxidant, polyphenolic, PD-1/PD-L1 inhibitor and TLR-8 agonist compounds and the effect on HBV-specific responses was further validated on additional 24 HLA-A2 negative CHB patients.

resultsSeverely exhausted HBV-specific CD8 T cell subsets with high expression of inhibitory receptors, such as PD-1, TOX and CD39, were detected only in a subgroup of chronic viraemic patients. Conversely, a large predominance of functionally more efficient HBV-specific CD8 T cell subsets with lower expression of coinhibitory molecules and better response to in vitro immune modulation, typically detected after resolution of infection, was also observed in a proportion of chronic viraemic HBV patients. Importantly, the same subset of patients who responded more efficiently to in vitro immune modulation identified by HBV-specific CD8 T cell analysis were also identified by staining total CD8 T cells with PD-1, TOX, CD127 and Bcl-2.

conclusionsThe possibility to distinguish patient cohorts with different capacity to respond to immune modulatory compounds in vitro by a simple analysis of the phenotypic CD8 T cell exhaustion profile deserves evaluation of its clinical applicability.

Indexed as

Hepatitis BHepatitis B, ChronicCD8-Positive T-LymphocytesHepatitis B virusHLA-A2 AntigenHumansProgrammed Cell Death 1 ReceptorHLA-A2 AntigenProgrammed Cell Death 1 Receptorcellular immunitychronic viral hepatitisimmune responseT lymphocytes

Identifiers

PMID36717219
PMCPMC10579518
OpenAlexW4318499568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.